

Table SI. Expression of PCNA in relation to clinicopathological features within the carcinomatous component of uterine carcinosarcomas.

Parameter	n	Expression level of PCNA		P-value
		Yes, n (%)	No, n (%)	
Age, years				0.1 <sup>a</sup>
<50	2	2 (100)	0	
50-60	5	1 (20)	4 (80)	
>60	23	9 (39)	14 (61)	
Carcinomatous component				0.129 <sup>b</sup>
Endometrioid	26	12 (46)	14 (54)	
Non-endometrioid	4	0	4 (100)	
Myometrial invasion				0.722 <sup>b</sup>
Yes	16	7 (44)	9 (56)	
No	14	5 (36)	9 (64)	
Lymphovascular space invasion				0.709 <sup>b</sup>
Yes	18	8 (44)	10 (56)	
No	12	4 (33)	8 (67)	
Stage (FIGO)				0.234 <sup>a</sup>
I	11	4 (36)	7 (64)	
II	6	3 (50)	3 (50)	
III	7	1 (14)	6 (86)	
IV	6	4 (67)	2 (33)	
Presence of tumor in the oviduct				0.391 <sup>b</sup>
Yes	7	4 (57)	3 (43)	
No	23	8 (35)	15 (65)	
Grade				0.204 <sup>a</sup>
G1	5	3 (60)	2 (40)	
G2	7	1 (14)	6 (86)	
G3	18	8 (44)	10 (56)	
Metastasis				1.0 <sup>b</sup>

Yes	12	5 (42)	7 (56)	
No	18	7 (39)	11 (61)	
Omental metastasis				0.018 <sup>b</sup>
Yes	4	4 (100)	0	
No	26	8 (31)	18 (69)	

<sup>a</sup>X<sup>2</sup>-Pearson's test; <sup>b</sup>Fisher's exact test. PCNA, proliferating cell nuclear antigen.

Table SII. Expression of MCM3 in relation to clinicopathological features within the carcinomatous component of uterine carcinosarcomas.

Parameter	n	Expression level of MCM3		P-value
		Yes, n (%)	No, n (%)	
Age, years				0.095 <sup>a</sup>
<50	2	2 (100)	0	
50-60	5	0	5 (100)	
>60	23	3 (13)	20 (87)	
Carcinomatous component				0.611 <sup>b</sup>
Endometrioid	26	9 (35)	17 (65)	
Non-endometrioid	4	2 (50)	2 (50)	
Myometrial invasion				1.0 <sup>b</sup>
Yes	16	6 (37)	10 (63)	
No	14	5 (36)	9 (64)	
Lymphovascular space invasion				0.442 <sup>a</sup>
Yes	18	8 (44)	10 (56)	
No	12	3 (25)	9 (75)	
Stage (FIGO)				0.0303 <sup>a</sup>
I	11	6 (55)	5 (45)	
II	6	1 (17)	5 (83)	
III	7	0	7 (100)	
IV	6	4 (67)	2 (33)	
Presence of tumor in the oviduct				0.371 <sup>b</sup>
Yes	7	4 (57)	3 (43)	
No	23	7 (30)	16 (70)	
Grade				0.377 <sup>a</sup>
G1	5	1 (20)	4(80)	

G2	7	4 (57)	3(43)	
G3	18	6 (33)	12(67)	
Metastasis				1.0 <sup>b</sup>
Yes	12	4 (33)	8 (67)	
No	18	7 (39)	11 (61)	
Omental metastasis				0.012 <sup>b</sup>
Yes	4	4 (100)	0	
No	26	7 (27)	19 (73)	

<sup>a</sup>X<sup>2</sup>-Pearson's test; <sup>b</sup>Fisher's exact test.

Table SIII. Expression of topoII $\alpha$  in relation to clinicopathological features within the carcinomatous component of uterine carcinosarcomas.

Parameter	n	Expression level of topoII $\alpha$		P-value
		Yes, n (%)	No, n (%)	
Age, years				0.170 <sup>a</sup>
<50	2	2 (100)	0	
50-60	5	2 (40)	3 (60)	
>60	23	9(39)	14 (61)	
Carcinomatous component				0.613 <sup>b</sup>
Endometrioid	26	12 (46)	14 (54)	
Non-endometrioid	4	1 (25)	3 (75)	
Myometrial invasion				
Yes	16	4 (25)	12 (75)	
No	14	9 (64)	5 (36)	
Lymphovascular space invasion				0.264 <sup>b</sup>
Yes	18	6 (33)	12 (67)	
No	12	7 (58)	5 (42)	
Stage (FIGO)				0.049 <sup>a</sup>
I	11	7 (64)	4 (36)	
II	6	1 (17)	5 (83)	
III	7	1 (14)	6 (86)	
IV	6	4 (67)	2 (33)	
Presence of tumor in the oviduct				0.666 <sup>b</sup>
Yes	7	4 (57)	3 (43)	
No	23	9 (39)	14 (61)	
Grade				0.164 <sup>a</sup>
G1	5	4 (80)	1 (20)	
G2	7	2 (29)	5 (71)	
G3	18	7 (39)	11 (61)	
Metastasis				1.0 <sup>b</sup>

Yes	12	5 (42)	7 (58)	
No	18	8 (44)	10 (56)	
Omental metastasis				0.026 <sup>b</sup>
Yes	4	4 (100)	0	
No	26	9 (35)	17 (65)	

<sup>a</sup>X<sup>2</sup>-Pearson's test; <sup>b</sup>Fisher's exact test. topoII $\alpha$ , topoisomerase II $\alpha$ .